Cerebrovascular Accident (CVA / Stroke) - Overview

CVA is a large topic. Here's the map of what it covers, based on standard neurology references (Bradley and Daroff's Neurology in Clinical Practice, and others in the library):

Definition & Classification - ischemic (~85%) vs hemorrhagic (~15%) stroke; TIA vs completed stroke
Risk Factors & Epidemiology - modifiable (HTN, AFib, diabetes, smoking, dyslipidemia) vs non-modifiable
Pathophysiology - ischemic cascade (thrombotic, embolic, lacunar), hemorrhagic mechanisms (intracerebral, subarachnoid)
Clinical Presentation & Localization - stroke syndromes by vascular territory (MCA, ACA, PCA, vertebrobasilar, lacunar syndromes)
Diagnostic Workup - NIHSS scoring, CT/MRI imaging, vascular imaging, cardiac workup, labs
Acute Management - IV thrombolysis (tPA) window and criteria, mechanical thrombectomy, blood pressure management, admission/monitoring
Secondary Prevention - antiplatelets, anticoagulation (for AFib), statins, carotid intervention, risk factor control
Complications & Rehabilitation - cerebral edema, hemorrhagic transformation, aspiration, DVT prophylaxis, physical/speech/occupational therapy

Brief overview: A CVA occurs when blood supply to part of the brain is disrupted, causing focal neurologic deficit. Ischemic stroke results from arterial occlusion (thrombosis, embolism, or small vessel disease), leading to a core of infarcted tissue surrounded by a salvageable "penumbra" - the target of acute reperfusion therapy. Hemorrhagic stroke results from vessel rupture (intracerebral hemorrhage or subarachnoid hemorrhage), causing direct tissue damage and mass effect. Clinical presentation depends entirely on the vascular territory involved - e.g. MCA strokes cause contralateral face/arm weakness and aphasia (if dominant hemisphere), while posterior circulation strokes cause vertigo, ataxia, and cranial nerve findings. Diagnosis hinges on rapid non-contrast CT to exclude hemorrhage before any thrombolytic is given, since ischemic and hemorrhagic stroke are managed in opposite ways. Time is brain: IV tPA and thrombectomy have strict time windows, which is why acute stroke protocols are so rigid.

Given the breadth here, tell me which area you want to go deep on and I'll build it out properly with textbook detail and images where useful.

Asking for Preferences

Which part of CVA do you want to go deep on first?

Cerebrovascular Accident (CVA / Stroke) - Overview

CVA is a large topic. Here's the map of what it covers, based on standard neurology references (Bradley and Daroff's Neurology in Clinical Practice, and others in the library):

Definition & Classification - ischemic (~85%) vs hemorrhagic (~15%) stroke; TIA vs completed stroke
Risk Factors & Epidemiology - modifiable (HTN, AFib, diabetes, smoking, dyslipidemia) vs non-modifiable
Pathophysiology - ischemic cascade (thrombotic, embolic, lacunar), hemorrhagic mechanisms (intracerebral, subarachnoid)
Clinical Presentation & Localization - stroke syndromes by vascular territory (MCA, ACA, PCA, vertebrobasilar, lacunar syndromes)
Diagnostic Workup - NIHSS scoring, CT/MRI imaging, vascular imaging, cardiac workup, labs
Acute Management - IV thrombolysis (tPA) window and criteria, mechanical thrombectomy, blood pressure management, admission/monitoring
Secondary Prevention - antiplatelets, anticoagulation (for AFib), statins, carotid intervention, risk factor control
Complications & Rehabilitation - cerebral edema, hemorrhagic transformation, aspiration, DVT prophylaxis, physical/speech/occupational therapy

Given the breadth here, tell me which area you want to go deep on and I'll build it out properly with textbook detail and images where useful.

History Points, Clinical Features. Investigations and Management of Cerebrovascular Accident.

Finding Sources

Searching PubMed

"ischemic stroke"[MeSH Terms] AND "thrombectomy"[MeSH Terms]

Searching Images

non-contrast CT scan showing acute ischemic stroke vs intracerebral hemorrhage

Finding Sources

Reading File

Cerebrovascular Accident (CVA / Stroke): History, Clinical Features, Investigations, Management

1. History Points

A focused stroke history should establish time of onset (critical for treatment eligibility) and localize the lesion.

Time last known well - the single most important data point; determines eligibility for thrombolysis/thrombectomy. If the patient woke up with deficits, "time last known normal" is when they went to sleep (wake-up stroke).
Onset pattern - sudden onset favors embolic/hemorrhagic stroke; stuttering or stepwise onset favors thrombotic/large-vessel disease; TIA-like preceding episodes suggest large-artery atherothrombotic disease.
Nature of symptoms - weakness/numbness (unilateral), speech disturbance, visual loss, vertigo, diplopia, ataxia, severe headache (suggests hemorrhage or SAH), decreased consciousness, seizure at onset.
Associated symptoms - "worst headache of life" and neck stiffness point toward subarachnoid hemorrhage; vomiting and headache with rapid deterioration suggest hemorrhagic stroke or raised ICP.
Vascular risk factors - hypertension, diabetes, dyslipidemia, smoking, atrial fibrillation, prior stroke/TIA, coronary artery disease, peripheral vascular disease, obesity, OSA.
Cardioembolic clues - palpitations, known AFib, recent MI, valvular disease, prosthetic valve, recent cardiac surgery.
Hypercoagulable/other clues - malignancy, pregnancy/postpartum, oral contraceptive use, recent long travel/immobilization (paradoxical embolism), illicit drug use (cocaine, amphetamines), young patient with no risk factors (consider dissection, vasculitis, patent foramen ovale).
Medication history - anticoagulants/antiplatelets (bleeding risk and thrombolysis contraindication), recent surgery or trauma, current antihypertensives.
Contraindication screen for thrombolysis - recent surgery, GI/GU bleeding, trauma, prior intracranial hemorrhage, anticoagulant use, recent stroke or MI, seizure at onset (this needs to be systematically asked once ischemic stroke is suspected).
Functional baseline - premorbid independence level (modified Rankin Scale), for prognosis and treatment-goal discussions.
Collateral history - from family/bystanders, since the patient may be aphasic or obtunded.

2. Clinical Features

General/localizing exam

Findings depend entirely on the vascular territory involved (Bradley and Daroff's Neurology in Clinical Practice):

Territory	Key features
MCA	Contralateral face/arm > leg weakness and sensory loss, aphasia (if dominant hemisphere), neglect/anosognosia (if non-dominant), homonymous hemianopia, gaze deviation toward the lesion
ACA	Contralateral leg > arm weakness, abulia/behavioral change, urinary incontinence
PCA	Contralateral homonymous hemianopia, visual agnosia, memory disturbance (if medial temporal involvement), alexia without agraphia (dominant)
Vertebrobasilar/posterior circulation	Vertigo, diplopia, dysarthria, ataxia, crossed sensory/motor findings, dysphagia, "locked-in" state if severe basilar occlusion
Lacunar syndromes	Pure motor hemiparesis, pure sensory stroke, ataxic hemiparesis, dysarthria-clumsy hand syndrome - no cortical signs (no aphasia, neglect, visual field cut)
Watershed/border-zone infarcts	Bilateral proximal arm/leg weakness ("man-in-a-barrel"), cortical blindness, visuospatial deficits

Hemorrhagic stroke-specific features

Sudden severe headache, vomiting, decreased consciousness, meningismus (especially SAH), and more rapid neurologic deterioration than typically seen with ischemic stroke, reflecting mass effect and raised ICP.

General exam

NIH Stroke Scale (NIHSS) should be performed on every acute stroke patient - it quantifies severity (0-42), guides treatment decisions (e.g. thrombectomy eligibility), and standardizes serial assessment (Bradley and Daroff's Neurology in Clinical Practice; Tintinalli's Emergency Medicine).
Cardiovascular exam (irregular pulse for AFib, carotid bruit, murmurs).
Fundoscopy (for signs of malignant hypertension/emboli).

3. Investigations

Immediate/first-line (within minutes of arrival):

Non-contrast CT head - the critical first study; primarily to exclude hemorrhage before considering thrombolysis. Ischemic changes may be subtle early (loss of grey-white differentiation, hyperdense MCA sign) - a hyperdense clot in the ICA/M1 segment can be seen directly on plain CT.
Blood glucose (bedside) - hypoglycemia is a critical stroke mimic that must be excluded immediately.
ECG - screen for atrial fibrillation and concurrent ischemia.
Basic bloods - CBC, electrolytes, renal function, coagulation profile (PT/INR, aPTT - especially if on anticoagulants), troponin.

Advanced imaging (where available, without delaying treatment):

CT angiography (CTA) - identifies large vessel occlusion, guides thrombectomy decision.
CT perfusion / MR perfusion-diffusion mismatch - defines the ischemic "core" versus salvageable "penumbra," used to extend treatment windows in select patients (basis of extended-window thrombectomy trials).
MRI with diffusion-weighted imaging (DWI) - most sensitive for acute infarct, especially posterior circulation/lacunar strokes where CT is often normal.

Etiologic workup (after acute phase, to guide secondary prevention):

Carotid duplex ultrasound / CTA / MRA neck vessels - for carotid stenosis in anterior circulation strokes.
Echocardiography (transthoracic +/- transesophageal) - for cardioembolic source (thrombus, valvular disease, PFO in younger patients).
Prolonged cardiac (telemetry/Holter) monitoring - to detect paroxysmal AFib, especially in cryptogenic stroke.
Lipid panel, HbA1c - risk factor assessment.
Hypercoagulable workup - in younger patients or those without typical risk factors (antiphospholipid antibodies, protein C/S, etc.)
TOAST classification is the standard etiologic framework: large-artery atherosclerosis, cardioembolism, small-vessel (lacunar), stroke of other determined etiology, and stroke of undetermined etiology (Bradley and Daroff's Neurology in Clinical Practice).

4. Management

A. Acute Ischemic Stroke

Modern therapy follows four approaches: general supportive care, reperfusion, cytoprotection, and anti-inflammatory strategies (Bradley and Daroff's Neurology in Clinical Practice).

IV thrombolysis (alteplase/tPA): within 3 hours of onset (established by NINDS trial), extendable to 4.5 hours in eligible patients (ECASS III). Strict inclusion/exclusion criteria apply (no recent surgery, no anticoagulation, no prior ICH, BP controlled below thrombolysis thresholds, no active bleeding).
Mechanical thrombectomy: for large vessel occlusion (ICA, M1/M2 segments), historically within 6 hours, extended up to 24 hours in selected patients using perfusion-based imaging selection (per DAWN/DEFUSE-3 trial design reflected in later guideline updates). Landmark trials (MR CLEAN, SWIFT PRIME, EXTEND-IA, ESCAPE, REVASCAT) showed strong benefit, with NNT for good outcome (mRS 0-2) as low as 3-7.
Blood pressure management: permissive hypertension is allowed in non-thrombolysed ischemic stroke (avoid aggressive lowering, which can worsen penumbral perfusion); tighter BP control (<180/105) required if tPA is given, to reduce hemorrhagic transformation risk.
General supportive measures: glucose control, temperature control, DVT prophylaxis, aspiration precautions/swallow assessment, early mobilization once stable, ICP management if malignant edema develops (osmotic therapy, decompressive hemicraniectomy in select malignant MCA infarcts).
Antithrombotics: aspirin started within 24-48 hours (once hemorrhage excluded and if no thrombolysis given within the last 24 hours); routine heparin/heparinoids are not recommended for general ischemic stroke as they haven't shown net benefit outside cerebral venous thrombosis.

B. Hemorrhagic Stroke

Reverse anticoagulation if applicable, strict BP control (lower thresholds than ischemic stroke, generally targeting SBP <140-160 depending on guideline), neurosurgical consultation for evacuation if indicated (large lobar hemorrhage, cerebellar hemorrhage with brainstem compression), ICP monitoring/management, and seizure prophylaxis in select cases.

C. Secondary Prevention (all stroke types, post-acute phase)

Antiplatelet therapy (aspirin, clopidogrel, or short-term dual antiplatelet therapy in select high-risk minor stroke/TIA) for non-cardioembolic stroke.
Anticoagulation (DOACs preferred over warfarin in most cases) for cardioembolic stroke, particularly atrial fibrillation.
Statin therapy - high-intensity statin regardless of baseline LDL in atherosclerotic stroke.
Risk factor control - BP, diabetes, smoking cessation.
Carotid revascularization - carotid endarterectomy or stenting for significant symptomatic carotid stenosis.
Rehabilitation - physical, occupational, and speech therapy started early; addresses the majority of long-term disability burden.

Recent evidence note

Guideline practice around thrombectomy has been evolving toward including large-volume/large-core infarcts, which were previously excluded from mechanical thrombectomy. Recent systematic reviews and meta-analyses of randomized trials support benefit in this population:

Hamo et al. 2025, Neurosurgery (PMID: 40387344) - thrombectomy for large-volume ischemic stroke, meta-analysis of 6 RCTs
Atchley et al. 2024, Neurosurgery (PMID: 37493372) - endovascular thrombectomy for large ischemic stroke

If you're studying this for exams, this large-core-thrombectomy expansion is a good point to flag as updating older teaching that restricted thrombectomy to smaller infarct cores.

Let me know if you want me to go deeper into any single piece - e.g. NIHSS scoring in detail, the TOAST classification, or a walkthrough of a specific stroke syndrome.

This is a shared conversation. Sign in to Orris to start your own chat.